Close

Boehringer Ingelheim to Purchase Amgen’s Fremont Facility

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Amgen Inc. and Boehringer Ingelheim announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen’s rights in and substantially all assets at Amgen’s Fremont California development and manufacturing facility. The transaction has been approved by the board of directors of each company and is expected to close in March of this year. The Amgen Fremont facility currently employs approximately 360 employees and is a state-of-the-art, 100,000-square-foot manufacturing facility with pilot plant and process development labs.

Prof. Dr. Wolfram Carius, Boehringer Ingelheim Board of Managing Directors said, With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies. The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global Contract Manufacturing Business including new biological entity process development and manufacturing efforts. We greatly value our relationship with Amgen and are enthusiastic about joining the San Francisco Bay Area biotechnology community and for the opportunity to better serve our current and future contract manufacturing customers.

Boehringer Ingelheim has been a contract manufacturer for Amgen for more than ten years.

Latest stories